Erectile Dysfunction (ED) Drugs Market: 4.76% YOY Growth Rate in 2022 | By Product (oral drugs, topical drugs, and others) and Geography | Growth,…

Erectile Dysfunction (ED) Drugs Market 2022-2026: Segmentation

The erectile dysfunction (ED) drugs market share growth by the oral drugssegment will be significant during the forecast period.Oral drugs have the advantage of high patient compliance due to easy route of administration and high bioavailability.These drugs have been dominating the market for a long time due to the ease of administration or self-administration. Moreover, the OTC availability of these drugs is a major factor that contributes to their large market share.The oral drugs segment is expected to exhibit decelerating growth during the forecast period. Most of the leading drugs used for the treatment of ED belong to this segment. The patent expiration of these drugs is paving the way for genericization, which is responsible for the declining growth of this segment.

39% of the market's growth will originate from North America during the forecast period. The USand Canada are the key markets forerectile dysfunction (ED) drugsin North America. Market growth in this region will be slower than the growth of the market in the European and Asian regions.

The increasing prevalence of chronic diseaseswill facilitate theerectile dysfunction (ED) drugs market growth in North America over the forecast period.

Download FREE Sample Report for more insights on the market share & contribution of various regions & segments

Increasing Prevalence of Chronic Diseases to Boost the Market Growth

Sexual dysfunction disorders are more common in women than in men and involve loss of desire, orgasm problems, and pain during sex. The onset of sexual dysfunction disorders in women is attributed to hormonal factors, menstrual irregularities, amenorrhea, lack of vaginal lubrication, and failure to conceive.Female sexual dysfunction can be caused due to various chronic diseases such as diabetes. Globally, diabetes is one of the most common chronic diseases. Patients with diabetes may have several clinical conditions, including overweight, hypertension, obesity, metabolic syndrome, cigarette smoking, and atherogenic dyslipidemia, which are risk factors for sexual dysfunction. The rising prevalence of these conditions across the globe is expected to increase the patient pool with a large number of men and women having sexual dysfunctions, which, in turn, will drive the growth of the global ED drugs market during the forecast period.

Patent Expiry of Blockbuster Drugs to Hamper the Market Growth

The blockbuster drugs dominating the global ED drugs market have already faced or are on the verge of facing patent expiration. The key drugs in the market include VIAGRA (Pfizer), CIALIS (Eli Lilly), and LEVITRA and STAXYN (Bayer). For instance, the patents for VIAGRA expired in December 2017 in the US. To recover the losses due to patent expiration, Pfizer has entered into a patent litigation settlement with Teva Pharmaceuticals and has launched the generic version of VIAGRA in the US in December 2017. For manufacturing the generic version of a drug, there are limited legal procedures, and the production expenses are also low. Hence, the market emergence of a wide range of generic versions, which are priced lower than the branded versions, is a major challenge faced by the market.

Download Free sample Report for insights on the Drivers, Trends, and Challenges that will help companies evaluate and develop growth strategies for 2022-2026

Our Erectile Dysfunction (ED) Drugs Market Report Covers the Following Areas:

Erectile Dysfunction (ED) Drugs Market 2022-2026: Vendor Analysis

The erectile dysfunction (ED) drugs market report offers information on several market vendors, including Aurobindo Pharma Ltd., Bayer AG, Cadila Healthcare Ltd., Cipla Ltd., Dr. Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Futura Medical plc, GlaxoSmithKline Plc, Innovcare Lifesciences Pvt. Ltd., Lupin Ltd., Pfizer Inc., SK Chemicals Co. Ltd., Teva Pharmaceutical Industries Ltd., TTK Healthcare Ltd., Viatris Inc., VIVUS Inc., and Sanzyme (P) Ltd. among others.

Moreover, the market is fragmented and the vendors are deploying growth strategies such asforming strategic alliances to increase their product offerings and geographical reachto compete in the market.

Download Our FREE Sample Report for more insights on vendors with product offerings & news

Erectile Dysfunction (ED) Drugs Market 2022-2026: Key Highlights

Related Reports:

Testosterone Replacement Therapy Market by Product and Geography - Forecast and Analysis: The testosterone replacement therapy market size has the potential to grow by USD113.54 million and the market's growth momentum will decelerateduring the forecast period. To get more exclusive research insights: Download Our FREE Sample Report

Sexual Enhancement Supplements Market by Product and Geography - Forecast and Analysis: The sexual enhancement supplements market size has the potential to grow by USD407.16 million and the market's growth momentum will accelerateduring the forecast period. To get more exclusive research insights: Download Our FREE Sample Report

Erectile Dysfunction (ED) Drugs Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 6.1%

Market growth 2022-2026

$ 1.20 billion

Market structure

Fragmented

YoY growth (%)

4.76

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 39%

Key consumer countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Aurobindo Pharma Ltd., Bayer AG, Cadila Healthcare Ltd., Cipla Ltd., Dr. Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Futura Medical plc, GlaxoSmithKline Plc, Innovcare Lifesciences Pvt. Ltd., Lupin Ltd., Pfizer Inc., SK Chemicals Co. Ltd., Teva Pharmaceutical Industries Ltd., TTK Healthcare Ltd., Viatris Inc., VIVUS Inc., and Sanzyme (P) Ltd.

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period,

Customization preview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of Contents:

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Product

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: [emailprotected]Website: http://www.technavio.com/

SOURCE Technavio

The rest is here:
Erectile Dysfunction (ED) Drugs Market: 4.76% YOY Growth Rate in 2022 | By Product (oral drugs, topical drugs, and others) and Geography | Growth,...